Abstract:Protein–protein interactions (PPIs) play a crucial role in essential cellular functions including cell division, transmembrane signaling, and protein recognition. Abnormal PPIs have been linked to human diseases, either due to improper formation and/or stabilization of a protein complex or the failure of an essential interaction [1]. This has led to the emergence of PPIs as a promising target in modern drug discovery. However, modulation of PPIs by small molecules has traditionally been considered a challenging task. The PPI interface has been classified as ‘undruggable,’ because the PPI interface area usually tends to be large and flat with limited grooves or pockets, making it difficult for small molecules to bind [1,2]. Despite these serious challenges, there have been several recent advancements in PPI modulation. Seven PPI modulators have been approved by the FDA for the treatment of chronic lymphocytic leukemia, HIV, Merkel cell carcinoma, and nonsmall cell lung cancer. Additionally, 24 PPI modulators, including small molecules, peptides, and antibodies, are currently undergoing clinical trials [3]. These developments highlight the great potential of PPIs as drug discovery target(s). In silico techniques play an essential role in the design of modulators for PPIs [2,4,5]. These computational methods allow for the identification of PPI interfaces between proteins and the prediction of potential binding sites for modulators. Once a target region has been identified, various virtual screening strategies can be employed to identify lead compounds for further investigation. These lead compounds can be further optimized by analyzing the mode of interaction between compounds and protein interfaces. The recent advancements in artificial intelligence (AI) have dramatically improved the application of in silico techniques. The design of modulators targeting PPIs will definitely benefit from this. The purpose of this editorial is to provide a concise overview of the current and future directions of in silico design of PPI modulators, particularly in the context of the integration of AI. It would be expected that this area of research will continue to evolve as the fast development of AI and computing power. 2. Directions that should be focused in the future

Where to next in the evolution of in silico design of modulators targeting protein–protein interactions?

Computational Methods-Guided Design of Modulators Targeting Protein-Protein Interactions (Ppis)

Computational Approaches for the Design of Modulators Targeting Protein-Protein Interactions

Evolution of In Silico Strategies for Protein-Protein Interaction Drug Discovery

New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials

State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors

Computational Modeling as a Tool to Investigate PPI: From Drug Design to Tissue Engineering

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Emerging Roles of Allosteric Modulators in the Regulation of Protein‐protein Interactions (ppis): A New Paradigm for PPI Drug Discovery

Targeting Protein-Protein Interaction by Small Molecules

Deciphering the Lexicon of Protein Targets: A Review on Multifaceted Drug Discovery in the Era of Artificial Intelligence

Allosteric Modulators of Protein-Protein Interactions (PPIs).

Protein–protein interaction modulator drug discovery: past efforts and future opportunities using a rich source of low- and high-throughput screening assays

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

AI for targeted polypharmacology: The next frontier in drug discovery

Artificial Intelligence for Autonomous Molecular Design: A Perspective

Main methods and tools for peptide development based on protein-protein interactions (PPIs)

Computational Peptidology: A New and Promising Approach to Therapeutic Peptide Design

Protein design: from computer models to artificial intelligence